Back to search results

Observational Study of Anti-Obesity Medications

This study is looking at the real-world effects of anti-obesity medications like semaglutide and tirzepatide in adults managing their weight. Researchers want to understand how these medications change your body composition (like lean muscle and fat), muscle strength, and what you eat. They will also look at how your lifestyle, such as exercise, affects these changes. You could join if you are 18 or older and starting treatment with semaglutide or tirzepatide through Vineyard Virtual Health Clinic. To be eligible for these medications, you must have a Body Mass Index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one related health condition. This is an observational study, meaning researchers will watch and collect information without giving you a specific intervention.

Study design
This is an observational study aiming to enroll 100 participants. It is not a randomized trial, meaning participants are not assigned to different treatment groups by chance.
What's involved
You would undergo periodic body composition and muscular performance tests. You would also complete online surveys about your nutrition and physical activity.
Compensation
Not stated in the trial record.
Follow-up
Follow-up assessments are conducted approximately 6 months and 17 months after your initial assessment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06790160

Study of Patients Being Treated With Anti-obesity Medication

Recruiting
Not specifiedAges 18+Observational
Texas Tech University
~100 participants
Updated 2026-05-15 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Total Lean Soft Tissue
Measured over From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).
+3 more outcomes measured

Conditions

Obesity and Overweight

Explore related trials

ObesityOverweight

Where it's being run

1 sites across 1 states
Texas1

Who to contact

Grant Tinsley, Ph.D.
[email protected]
806-834-5895
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient who is beginning treatment through Vineyard Virtual Health Clinic using semaglutide or tirzepatide. While the physician will individualize the treatment plans, the criteria for these medications will include, at a minimum: (A) a body mass index ≥30 kg/m2; OR (B) a BMI ≥27 kg/m2 plus at least one comorbidity.
Patient who lives in drivable proximity to a city with an accepted DXA testing facility and is willing to report to the facility for periodic body composition testing.

Exclusion

Patients with type 2 diabetes.
Patients who report not being willing or able to complete the assessments included in this research study.
Patients who are currently pregnant or trying to become pregnant.

What this trial measures

  • Change in Total Lean Soft TissueFrom baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).

    Change in total lean soft tissue assessed by dual-energy X-ray absorptiometry.

  • Change in Appendicular Lean Soft TissueFrom baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).

    Change in appendicular lean soft tissue assessed by dual-energy X-ray absorptiometry.

  • Change in Total Fat MassFrom baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).

    Change in total fat mass assessed by dual-energy X-ray absorptiometry.

  • Change in Handgrip StrengthFrom baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).

    Change in maximal handgrip strength as determined by a handgrip dynamometer.